KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Accumulated Expenses: 2017-2024

Historic Accumulated Expenses for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $5.9 million.

  • Aquestive Therapeutics' Accumulated Expenses rose 2.05% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 2.05%. This contributed to the annual value of $5.9 million for FY2024, which is 9.08% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported Accumulated Expenses of $5.9 million as of FY2024, which was down 9.08% from $6.5 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Accumulated Expenses ranged from a high of $8.7 million in FY2021 and a low of $5.9 million during FY2024.
  • For the 3-year period, Aquestive Therapeutics' Accumulated Expenses averaged around $6.8 million, with its median value being $6.5 million (2023).
  • As far as peak fluctuations go, Aquestive Therapeutics' Accumulated Expenses soared by 56.51% in 2020, and later dropped by 18.45% in 2023.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Accumulated Expenses stood at $8.6 million in 2020, then climbed by 1.95% to $8.7 million in 2021, then fell by 8.80% to $8.0 million in 2022, then declined by 18.45% to $6.5 million in 2023, then dropped by 9.08% to $5.9 million in 2024.